Supernus Pharmaceuticals, Inc.
SUPN
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $2.6B
$44.03
▲ +0.66%
P/E
-86.10
Mkt Cap
$2.6B
52-Wk Range
$42.45–$59.68
52-Week Range
$42.45 - $59.68
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 2.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Established commercial portfolio with FDA-approved products generating consistent revenue
- Specialized expertise in CNS drug formulation, particularly extended-release technologies
- Late-stage pipeline addressing significant unmet medical needs in neurology and psychiatry
- Strategic focus on specialty pharmaceutical distribution channels with high barriers to entry
- Diversified product portfolio reducing reliance on single therapeutic indication
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Turning profitable
Steady revenue growth (9% YoY)
Value
Attractively priced below Biotech & Therapeutics peer average
Momentum
Stable
-0.0% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying SUPN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 3, 2026
Reported EPS of $0.54 vs $0.42 consensus (+27.8% surprise). Revenue of $219.1M vs $205.3M expected (+6.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+27.8%
Revenue trend · last 8Q
—
—
+6%
+4%
-2%
+9%
+21%
+39%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$168.3M
$175.7M
$174.2M
$149.8M
$165.5M
$192.1M
$211.6M
$207.7M
Margins · last 8Q
Gross
—
Operating
—
Profit
-1.1%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How SUPN stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related